Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Upadacitinib in Pediatric Subjects With Polyarticular Course Juvenile Idiopathic Arthritis
NCT03725007Phase 1Active, not recruiting
- Sponsor
- AbbVie Inc.
- Start
- Jun 2019
- Primary completion
- Dec 2028
- Modality
- Small Molecules
- Countries
- 10
01
Overview
Phase 1, open-label trial of upadacitinib in juvenile idiopathic arthritis (JIA) (5 arms), sponsored by AbbVie Inc. Primary endpoints: Treatment Emergent Adverse Events at 260 weeks, Maximum observed plasma concentration at 7 days and 4 more. Started Jun 2019; status: active, not recruiting.
02
Drugs
upadacitinib
03
Conditions
juvenile idiopathic arthritis (JIA)
Beyond the preview
Go deeper on NCT03725007.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03725007.